22 June 2020>: Clinical Research
Retrospective Analysis of Clinical Outcomes in Patients with Immunoglobulin A Nephropathy and Persistent Hematuria Following Renin-Angiotensin System Blockade
Jingjing Chen 12ACE , Shao Liu 1ADE , Hui Xu 23AF* , Wei Wang 3BC , Yanyun Xie 3B , Wenbin Tang 3B , Qiongjing Yuan 3B , Li Zheng 4D , Lizhen Lin 35F , Shuangshuang Fu 6F , Jinmei Shen 7CDOI: 10.12659/MSM.922839
Med Sci Monit 2020; 26:e922839
Supplementary Table 1 Baseline characteristics of the matched IgAN patients only with hematuria initially (n=103).
Characteristics at biopsy | Treatment group (n=37) | Untreated group (n=66) | P |
---|---|---|---|
Clinical characteristics | |||
Male (%) | 10 (27.0) | 17 (25.8) | 0.89 |
Age (years) | 31±12 | 29±10 | 0.29 |
Serum creatinine (μmol/L) | 72.0 (59.0–86.5) | 71.0 (58.8–77.5) | 0.26 |
Initial eGFR (ml/min/1.73 m) | 102.2±23.7 | 107.9±25.2 | 0.26 |
Hematuria, (cells/hpf) | 37.0 (27.0–71.0) | 33.0 (13.0–68.0) | 0.14 |
Systolic pressure (mmHg) | 120 (108–128) | 118 (104–124) | 0.53 |
Diastolic pressure (mmHg) | 76 (70–84) | 71 (65–80) | 0.18 |
Hypertension, n (%) | 5 (13.5) | 5 (7.6) | 0.49 |
Hemoglobin (g/L) | 127 (116–131) | 127 (117–134) | 0.69 |
Albumin (g/L) | 42.1±4.6 | 42.1±4.4 | 0.96 |
Uric acid (μmol/L) | 288 (227–339) | 283 (255–309) | 0.67 |
Low hemoglobin, n (%) | 4 (10.8) | 8 (12.1) | 1.00 |
Hypoalbuminemia, n (%) | 2 (5.4) | 3 (4.5) | 1.00 |
Hyperuricemia, n (%) | 4 (10.8) | 7 (10.6) | 1.00 |
Biopsy characteristics | |||
M1, n (%) | 21 (56.8) | 30 (45.5) | 0.27 |
E1, n (%) | 7 (18.9) | 16 (24.2) | 0.53 |
S1, n (%) | 15 (40.5) | 20 (30.3) | 0.29 |
T1–2, n (%) | 1 (2.7) | 5 (7.6) | 0.42 |
C1–2, (%)* | 3 (8.1) | 4 (6.1) | 0.70 |
Duration from initial diagnosis to start of therapy (months) | 5.0 (1.0–21.0) | 5.6 (1.0–12.0) | 0.94 |
* Crescents >50% were excluded. eGFR – estimated glomerular filtration rate; RASB – reninangiotensin system blockers; M – mesangial hypercellularity; E–endocapillary hypercellularity; S – segmental glomerulosclerosis; T – tubular atrophy/interstitial fibrosis; C – crescent. |